Lyell Immunopharma (LYEL) Change in Acquisitions & Divestments (2020 - 2026)

Lyell Immunopharma has reported Change in Acquisitions & Divestments for 7 years, with the latest figure at $54.6 million in Q1 2026.

• Quarterly Change in Acquisitions & Divestments fell 64.54% year-over-year to $54.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $275.2 million (down 51.97% YoY) and the FY2025 annual result came in at $374.7 million, down 31.74% from the prior year.
• Change in Acquisitions & Divestments advanced to $54.6 million in Q1 2026 per LYEL's latest filing, from $52.9 million in the prior quarter.
• Over five years, Change in Acquisitions & Divestments peaked at $187.1 million in Q2 2023 and troughed at $52.9 million in Q4 2025.
• A 5-year average of $121.2 million and a median of $123.7 million in 2024 frame the typical range for Change in Acquisitions & Divestments.
• The sharpest annual moves came in 2023 and 2026: Change in Acquisitions & Divestments jumped 78.24% in 2023, then tumbled 64.54% in 2026.
• Over 5 years, Change in Acquisitions & Divestments stood at $110.9 million in 2022, then surged by 40.78% to $156.1 million in 2023, then declined by 20.77% to $123.7 million in 2024, then sank by 57.23% to $52.9 million in 2025, then climbed by 3.29% to $54.6 million in 2026.
• According to Business Quant data, Change in Acquisitions & Divestments over the past three periods registered $54.6 million, $52.9 million, and $74.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.